Evan Seigerman
Stock Analyst at BMO Capital
(3.33)
# 371
Out of 5,182 analysts
154
Total ratings
54.9%
Success rate
13.22%
Average return
Main Sectors:
Stocks Rated by Evan Seigerman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NBIX Neurocrine Biosciences | Maintains: Market Perform | $147 → $140 | $128.12 | +9.27% | 16 | Feb 12, 2026 | |
| BIIB Biogen | Maintains: Market Perform | $165 → $196 | $183.38 | +6.88% | 28 | Feb 9, 2026 | |
| TERN Terns Pharmaceuticals | Maintains: Outperform | $35 → $54 | $52.94 | +2.00% | 3 | Dec 9, 2025 | |
| LLY Eli Lilly and Company | Maintains: Outperform | $1,100 → $1,200 | $874.00 | +37.30% | 10 | Dec 4, 2025 | |
| GILD Gilead Sciences | Maintains: Outperform | $120 → $130 | $129.26 | +0.57% | 18 | Aug 8, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Outperform | $557 → $530 | $430.14 | +23.22% | 16 | Aug 5, 2025 | |
| INCY Incyte | Maintains: Underperform | $52 → $60 | $97.74 | -38.61% | 13 | Jul 30, 2025 | |
| IRON Disc Medicine | Maintains: Outperform | $112 → $120 | $67.26 | +78.41% | 6 | May 12, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Market Perform | $57 → $61 | $58.26 | +4.70% | 11 | Nov 12, 2024 | |
| GPCR Structure Therapeutics | Initiates: Outperform | $40 | $43.56 | -8.17% | 1 | Feb 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $40 | $2.57 | +1,456.42% | 1 | Oct 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $757 → $788 | $731.77 | +7.68% | 17 | Aug 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $8 → $2.5 | $4.56 | -45.18% | 2 | Aug 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $263 → $243 | $339.57 | -28.44% | 6 | Apr 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $12 | $6.20 | +93.55% | 2 | Mar 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $60 | $26.48 | +126.59% | 1 | Nov 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $13 → $30 | $3.01 | +896.68% | 3 | May 12, 2020 |
Neurocrine Biosciences
Feb 12, 2026
Maintains: Market Perform
Price Target: $147 → $140
Current: $128.12
Upside: +9.27%
Biogen
Feb 9, 2026
Maintains: Market Perform
Price Target: $165 → $196
Current: $183.38
Upside: +6.88%
Terns Pharmaceuticals
Dec 9, 2025
Maintains: Outperform
Price Target: $35 → $54
Current: $52.94
Upside: +2.00%
Eli Lilly and Company
Dec 4, 2025
Maintains: Outperform
Price Target: $1,100 → $1,200
Current: $874.00
Upside: +37.30%
Gilead Sciences
Aug 8, 2025
Maintains: Outperform
Price Target: $120 → $130
Current: $129.26
Upside: +0.57%
Vertex Pharmaceuticals
Aug 5, 2025
Maintains: Outperform
Price Target: $557 → $530
Current: $430.14
Upside: +23.22%
Incyte
Jul 30, 2025
Maintains: Underperform
Price Target: $52 → $60
Current: $97.74
Upside: -38.61%
Disc Medicine
May 12, 2025
Maintains: Outperform
Price Target: $112 → $120
Current: $67.26
Upside: +78.41%
Bristol-Myers Squibb Company
Nov 12, 2024
Maintains: Market Perform
Price Target: $57 → $61
Current: $58.26
Upside: +4.70%
Structure Therapeutics
Feb 28, 2023
Initiates: Outperform
Price Target: $40
Current: $43.56
Upside: -8.17%
Oct 14, 2022
Maintains: Outperform
Price Target: $30 → $40
Current: $2.57
Upside: +1,456.42%
Aug 4, 2022
Maintains: Outperform
Price Target: $757 → $788
Current: $731.77
Upside: +7.68%
Aug 2, 2022
Downgrades: Market Perform
Price Target: $8 → $2.5
Current: $4.56
Upside: -45.18%
Apr 28, 2022
Maintains: Market Perform
Price Target: $263 → $243
Current: $339.57
Upside: -28.44%
Mar 31, 2022
Maintains: Outperform
Price Target: $18 → $12
Current: $6.20
Upside: +93.55%
Nov 19, 2021
Initiates: Outperform
Price Target: $60
Current: $26.48
Upside: +126.59%
May 12, 2020
Maintains: Outperform
Price Target: $13 → $30
Current: $3.01
Upside: +896.68%